# Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer

> **NCT00072033** · PHASE2 · COMPLETED · sponsor: **Swiss Cancer Institute** · enrollment: 66 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Cisplatin and Docetaxel

## Key facts

- **NCT ID:** NCT00072033
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2003-03
- **Final completion:** 2010-05
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072033, "Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00072033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*